Epigenetic cancer therapy makes headway.
Mack
George S
GS
D000107:Acetylation / Q000187:drug effects; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D001374:Azacitidine / Q000031:analogs & derivatives / Q000494:pharmacology; D019175:DNA Methylation / Q000187:drug effects; D000077209:Decitabine; D044127:Epigenesis, Genetic / Q000187:drug effects*; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D006655:Histone Deacetylases / Q000494:pharmacology; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology; D008780:Methyltransferases / Q000494:pharmacology; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics; D016032:Randomized Controlled Trials as Topic; D014635:Valproic Acid / Q000494:pharmacology; D000077337:Vorinostat
D000970:Antineoplastic Agents; D006877:Hydroxamic Acids; D000077337:Vorinostat; D014635:Valproic Acid; D000077209:Decitabine; D008780:Methyltransferases; D006655:Histone Deacetylases; D001374:Azacitidine